Sirolimus-induced inflammatory papules with acquired reactive perforating collagenosis.
Sirolimus is an immunosuppressive macrolide with antineoplasic properties that is increasingly used in posttransplantation immunosuppression. The treatment is frequently associated with cutaneous side effects such as sirolimus-associated acneiform facial dermatitis, which has been observed in up to 50% of treated patients. We report a 51-year-old female with liver transplantation who developed inflammatory papules and nodules on the face and the upper chest 3 weeks after the initiation of sirolimus therapy. Sequential biopsies revealed lymphocytic infiltration of the dermis with a peculiar pattern of sebotropism, while older lesions showed acquired reactive perforating collagenosis. The lesions were responsive to hydroxychloroquine treatment despite continued sirolimus treatment.
Lübbe
J
J
Clinique et Policlinique de Dermatologie et Vénéréologie, Hôpital Cantonal Universitaire de Genève, Geneva, Switzerland. jann.lubbe@hcuge.ch
Sorg
O
O
Malé
P J
PJ
Saurat
J H
JH
Masouyé
I
I
D017486:Acneiform Eruptions / Q000139:chemically induced* / Q000188:drug therapy / Q000473:pathology; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D003094:Collagen / Q000032:analysis; D003095:Collagen Diseases / Q000139:chemically induced* / Q000188:drug therapy / Q000473:pathology; D003875:Drug Eruptions / Q000209:etiology*; D005260:Female; D006801:Humans; D006886:Hydroxychloroquine / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D016031:Liver Transplantation; D008875:Middle Aged; D012627:Sebaceous Glands / Q000473:pathology; D012629:Sebum / Q000737:chemistry; D020123:Sirolimus / Q000009:adverse effects* / Q000493:pharmacokinetics; D012867:Skin / Q000473:pathology
D000893:Anti-Inflammatory Agents; D007166:Immunosuppressive Agents; D006886:Hydroxychloroquine; D003094:Collagen; D020123:Sirolimus